Related Experiment Videos
Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients.
Psychiatry Research
|September 1, 1991
Summary
This study found that Chinese schizophrenic patients require higher plasma haloperidol (HAL) levels than non-Chinese patients. A suggested upper therapeutic limit of 25 ng/ml can be achieved with approximately 30 mg/day of HAL.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Chemistry
Background:
- Schizophrenia treatment often involves haloperidol (HAL).
- Understanding plasma concentration-response relationships is crucial for optimizing therapy.
- Inter-individual variability in drug metabolism necessitates population-specific pharmacokinetic studies.
Purpose of the Study:
- To determine plasma concentrations of haloperidol (HAL) and reduced HAL (RHAL) in Chinese schizophrenic patients.
- To establish the relationship between HAL dosage and plasma levels in this population.
- To suggest an optimal therapeutic range for HAL in Chinese patients.
Main Methods:
- Blood samples were collected from 113 Chinese schizophrenic patients under steady-state conditions.
- Plasma HAL and RHAL concentrations were quantified using high-performance liquid chromatography.
- Pharmacokinetic data were analyzed to correlate plasma levels with daily dosages.
Main Results:
- Significant interpatient variation in plasma HAL levels was observed.
- A strong positive correlation was found between HAL dosage and plasma levels.
- Plasma HAL levels in Chinese patients were 15-55% higher than reported for non-Chinese populations.
- The reduced HAL to HAL (RHAL/HAL) ratio increased with dosage.
Conclusions:
- Chinese schizophrenic patients may require higher HAL dosages to reach therapeutic plasma levels.
- An upper therapeutic limit of 25 ng/ml for plasma HAL is proposed, achievable at ~30 mg/day.
- The dose-dependent RHAL/HAL ratio suggests RHAL's importance in HAL treatment efficacy.